Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
NEWARK, Del. & MEDFORD, Mass.--(BUSINESS WIRE)--QPS Holdings, LLC, a US-headquartered contract research organization (“CRO”), and Hepregen Corporation, developer of HepatoPacTM and HepatoMuneTM “liver-in-a-dish” products, announced today the execution of an agreement between the companies that provides QPS a license to offer drug metabolism and pharmacokinetic (“DMPK”) services to its clients using Hepregen’s unique, paradigm-shifting products. The agreement provides for offerings in both North America and Europe. The agreement also creates a marketing and sales partnership between the companies, providing for co-promotion of the HepatoPacTM-associated DMPK services. This arrangement is the first such partnership in the field for both companies.
Help employers find you! Check out all the jobs and post your resume.
